Use of loop diuretics in heart failure: Current aspects

Kurlykina N.V.; Seredenina E.M.; Orlova Ia.A.

doi:https://doi.org/10.17116/terarkh2017899115-119

Close metadata

Recommended articles:

Transapical myectomy in a child with hypertrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):357-362

Rapidly progressive periodontitis. (A successful experience of eighteen years of observation). Russian Journal of Stomatology. 2025;(2):61-67

Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76

Bacterial vaginosis: modern views. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):261-268

Method of photodynamic action in surgical treatment of local limited peritonitis in the experiment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86

Appendicular diverticulum in acute appendix. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):117-120

Optimal cardioplegia for coronary artery bypass grafting in patients with heart failure: a randomized study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):405-411

Features of the clinical course of multiple sclerosis as a factor in persistent disability. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44

Traumatic injuries of the rectum and anus in childhood. Pirogov Russian Journal of Surgery. 2025;(8):62-66

Course and outcomes of pregnancy in patients with multiple pregnancies with rhesus isoimmunization. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):59-65

Abstract:

Loop diuretics take the lead in the treatment of patients with symptomatic heart failure. Torasemide is the most effective and safe loop diuretic with the optimal pharmacokinetic profile, the additional properties associated with simultaneous blockade of the renin-angiotensin-aldosterone system and with the antiadrenergic effects of the drug, its positive impact on myocardial fibrosis and minimal severe potential negative effects. Sustained-release torasemide provides a more comfortable removal of excess liquid and does not deteriorate quality of life.

Keywords:

diuretics

torasemide

treatment

heart failure

Authors:

Kurlykina N.V.

Medical Education Research Center, M.V. Lomonosov Moscow State University, Moscow, Russia

Seredenina E.M.

Medical Education Research Center, M.V. Lomonosov Moscow State University, Moscow, Russia

Orlova Ia.A.

NII kardiologii im. A.L. Miasnikova FGBU RKNPK Minzdrava Rossii, Moskva

Close metadata

References:

Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016. https://doi.org/10.1161/circulationaha.109.192064
Mareev VYu, Ageev FT, Arutyunov GP , Koroteev AV, Mareev YuV, Ovchinnikov AG, Belenkov YuN, Vasyuk YuA, Galyavich AS, Garganeeva AA, Gilyarevskii SR, Glezer MG, Koziolova NA, Kots YaI, Lopatin YuM, Martynov AI, Moiseev VS, Revishvili ASh, Sitnikova MYu, Skibitskii VV, Sokolov EI, Storozhakov GI, Fomin IV, Chesnikova AI, Shlyakhto EV, Akchurin RS, Aronov DM, Arkhipov MV, Bart BYa, Belousov YuB, Boitsov SA, Gendlin GE, Golikov AP, Golitsyn SP, Gurevich MA, Danielyan MO, Dovgalevskii PYa, Zadionchenko VS, Karpov RS, Karpov YuA, Kobalava ZhD, Kuznetsov VA, Lazebnik LB, Nasonov EL, Nedogoda SV, Nikitin YuP, Oganov RG, Panchenko EP, Perepech NB, Podzolkov VI, Pozdnyakov YuA, Rakov AL, Ruda MYa, Rylova AK, Simonenko VB, Sidorenko BA, Staroverov II, Sulimov VA, Tarlovskaya EI, Tereshchenko SN, Fomina IG, Chazova IE, Drapkina OM. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Serdechnaya Nedostatochnost’. 2013;14;7(81):1-94. (In Russ.).
Arueira HB, Mesquita ET, Kang HC, Miranda VA, Ramos CS, Rosa MLG. Low quality of life as an additional criterion for the clinical diagnosis of heart failure in primary care. Rev Port Cardiol. 2012;31(9):559-565. https://doi.org/10.1016/j.repc.2012.06.004
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197. https://doi.org/10.1161/cir.0b013e3182456d46
Vaduganathan M, Fonarow GC. Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. Heart Fail Clin. 2013;9(3):271-276. https://doi.org/10.1016/j.hfc.2013.04.001
Gurevich MA. Khronicheskaya serdechnaya nedostatochnost’: Rukovodstvo dlya vrachei. M.: MIA; 2005:280. (In Russ.).
Cleland JG, Tendera M, Adamus J, Freemantle N Polonski L Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-2345. https://doi.org/10.1093/eurheartj/ehl250
Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154:1905-1914. https://doi.org/10.1001/archinte.1994.00420170045004
Coletta AP, Clark AL, Cleland JG. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA. Eur J Heart Fail. 2009; 11(2):214-219. https://doi.org/10.1093/eurjhf/hfn047
Drechsler K, Dietz R, Klein H, Wollert KC, Storp D, Molling J, Zeymer U, Niebauer J. Euro heart failure survey. Medical treatment not in line with current guidelines. Z Kardiol. 2005;94(8):510-515. https://doi.org/10.1007/s00392-005-0245-y
Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Badin YuV, Galyavich AS, Danielyan MO, Kamalov GM, Kolbin AA, Kechedzhieva SG, Makarova VG, Makarova NV, Malenkova VYu, Saifutdinov RI3, Tarlovskaya EI, Khokhlov RA, Shcherbinina EV, Yakushin SS. Prevalence of chronic heart failure in the European part of the Russian Federation: data from EPOCH-CHF. Serdechnaya nedostatochnost’. 2006;7(1):112-115. (In Russ.).
Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Badin YuV, Galyavich AS, Danielyan MO, Kamalov GM, Kolbin AA, Kechedzhieva SG, Makarova VG, Makarova NV, Malenkova VYu, Saifutdinov RI, Tarlovskaya EI, Khokhlov RA, Shcherbinina EV, Yakushin SS. Prevalence of chronic heart failure in the European part of the Russian Federation: data from EPOCH-CHF. Serdechnaya nedostatochnost’. 2006;7(3):3-7. (In Russ.).
Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Сердечная недостаточность. 2013;14;7(81):1-91.
Brater D. Torasemide: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3(Suppl.G):19-24.
Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno M A, Zalba G, Diez J. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34:138-143. https://doi.org/10.1161/01.hyp.34.1.138
Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart. 2006;92:1434-1440. https://doi.org/10.1136/hrt.2005.079764
Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M, Isobe S, Cheng XW, Noda A, Nagata K, Yokota M, Murohara T. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009;53:468-473. https://doi.org/10.1097/fjc.0b013e3181a717f7
Bolke T, Achhammer I. Torasemide review of its pharmacology and therapeutic use. Drugsof Today. 1994;30(8):1-28.
Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205:145-150. https://doi.org/10.1016/0014-2999(91)90812-5
Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-50. https://doi.org/10.1016/s0024-3205(98)00265-3
Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M, Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384-390. https://doi.org/10.1253/circj.67.384
Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708. https://doi.org/10.1016/S0735-1097(03)00765-4
Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-513. https://doi.org/10.1016/s1388-9842(02)00122-8
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520. https://doi.org/10.1016/s0002-9343(01)00903-2
Mareev VYu, Vygodin VA, Belenkov YuN. Diuretic therapy with effective doses of oral diuretics torasemide and furasemide in the treatment of patients with exacerbation of chronic cardiac failure. Serdechnaya nedostatochnost’. 2011;12,№1(63):3-10. (In Russ.).
Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801. https://doi.org/10.1016/s1388-9842(03)00150-8
DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8:707-728. https://doi.org/10.2217/fca.12.54
Dominik G. Haider, Gregor Lindner, et al. Use of Diuretics is not associated with mortality in patients admitted to the emergency department: results from a cross-sectional study. J Negat Results Biomed. 2016;15:1. https://doi.org/10.1186/s12952-016-0044-1
Robert J Mentz, Eric J Velazquez, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O’Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial September 2015,Vol. 11, No. 5, Pages 585-595. https://doi.org/10.2217/fca.15.56
Mentz RG, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WHW, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O’Connor CM. Torsemide versus Furosemide in Patients with Acute Heart Failure (From the ASCEND-HF Trial). Am J Cardiol. 2016;117(3):404-411. https://doi.org/10.1016/j.amjcard.2015.10.059
Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-2035. https://doi.org/10.1016/j.jacc.2003.12.052
Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:859-867. https://doi.org/10.1016/j.jacc.2007.04.080
López B, Querejeta R, González A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009;53(2):236-242. https://doi.org/10.1161/hypertensionaha.108.125278
Han LN, Guo SL, Lin XM, Shi XM, Zang CB, Yang LM, Ding GL. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res. 2014;13(3):7262-7274. https://doi.org/10.4238/2014.september.5.11
Effects of Prolonged-Release Torasemide Versus Furosemide on Miocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded-End Point. Active-Controlled Study. The TORAFIC Investigators Group. Clin Ther. 2011;33: 1204-1213. https://doi.org/10.1016/j.clinthera.2011.08.006
Tsutamoto T., Sakai H., Wada A., Ishikawa C., Ohno K., Fujii M., Yamamoto T., Takayama T., Dohke T., Horie M. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2252-2253. https://doi.org/10.1016/j.jacc.2004.09.009
Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Böhm M, Laufs U. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J Mol Cell Cardiol. 2015;85:140-150. https://doi.org/10.1016/j.yjmcc.2015.05.019
abstract. Basic Clin Pharmacol Toxicol. 2006;99(Suppl.1):48.
Barbanoj MJ, Ballester MR, Antonijoan RM, Gich I, Pelagio P, Gropper S, Santos B, Guglietta A. Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers. Fundam Clin Pharmacol. 2009;23(1):115-125. https://doi.org/10.1111/j.1472-8206.2008.00643.x
Reyes А. Effects of diuretics on renal excretory function. Eur Heart J. 1992;13(Suppl.G):15021. https://doi.org/10.1093/eurheartj/13.suppl_g.15
Arutyunov GP, Oganezova LG, Dragunov DO. Interrelation between of the half-life of loop diuretics, the severity of natriuresis and Central hemodynamics indices in patients with CHF (pilot study). Serdechnaya nedostatochnost’. 2012;(13):4(72):222-227. (In Russ.). https://doi.org/10.18087 / rhfj.2012.4.1715
Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Sokolova AV. Effect of Dosage Forms Loop Diuretic With a Different Release Rate for Early and Delayed the Prognosis of Patients With Circulatory Decompensation. Kardiologiya. 2014;(9):24-32. (In Russ.).